The University of Chicago Header Logo

Connection

Amittha Wickrema to Myelodysplastic Syndromes

Back to Details
This is a "connection" page, showing publications Amittha Wickrema has written about Myelodysplastic Syndromes.
Amittha Wickrema
Connection Strength
2.238
Myelodysplastic Syndromes
  1. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. Clin Cancer Res. 2019 09 15; 25(18):5638-5649.
    View in: PubMed
    Score: 0.523
  2. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):E6359-68.
    View in: PubMed
    Score: 0.404
  3. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022 08 30; 11.
    View in: PubMed
    Score: 0.162
  4. Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes. Cancer Med. 2019 03; 8(3):1169-1174.
    View in: PubMed
    Score: 0.127
  5. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 12 03; 128(12):5479-5488.
    View in: PubMed
    Score: 0.125
  6. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.117
  7. Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/ß-Catenin Activation. Cancer Res. 2017 09 15; 77(18):4846-4857.
    View in: PubMed
    Score: 0.114
  8. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016 11; 101(11):1426-1433.
    View in: PubMed
    Score: 0.107
  9. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.
    View in: PubMed
    Score: 0.098
  10. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015 May 14; 125(20):3144-52.
    View in: PubMed
    Score: 0.097
  11. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9.
    View in: PubMed
    Score: 0.083
  12. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem. 2011 Jul 15; 286(28):25211-23.
    View in: PubMed
    Score: 0.074
  13. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb 01; 71(3):955-63.
    View in: PubMed
    Score: 0.072
  14. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008 Oct 15; 112(8):3434-43.
    View in: PubMed
    Score: 0.060
  15. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.049
  16. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.